Application of autologous multipotent mesenchymal stromal cells for correction of liver function in patients suffering from alcoholic liver cirrhosis
- Authors: Kotkas I.E.1, Masurov V.I.1, Bakulin I.G.1, Enukashvili N.I.1, Asadulayev S.M.1
- 
							Affiliations: 
							- North-Western State Medical University named after I.I. Mechnikov
 
- Issue: Vol 22, No 4 (2020)
- Pages: 33-36
- Section: Clinical trials
- URL: https://journal-vniispk.ru/1682-7392/article/view/62801
- DOI: https://doi.org/10.17816/brmma62801
- ID: 62801
Cite item
Abstract
Clinical experience of application of autologous multipotent mesenchymal stromal cells in treatment of patient suffering from liver cirrhosis of alcoholic etiology is presented. A special feature is that the hepatocyte precursors were isolated directly from the patient’s liver tissue. The patient underwent laparoscopic surgery to obtain the largest volume of material and to be able to visually control the tissue sampling with minimal fibrotic changes. After liver tissue sampling, the patient was discharged for outpatient treatment in a satisfactory condition. Subsequently, the patient was re-admitted to the hospital. During repeated hospitalization, multipotent mesenchymal stromal cells in the amount of 20 million were injected into the arterial bed of the liver using x-ray endovascular technique. In the control study, 6 months after treatment, according to the 13C-metacetin test, normalization of liver function, regression of portal hypertension, and an increase in platelet levels were noted. There were no complications during this treatment. Treatment of patients suffering from cirrhosis of the liver is quite a serious and complex task. As a rule, the patient learns about his diagnosis already in the presence of complications, when the liver function is already significantly impaired. The propensity of the population to alcoholism leads to the formation of fibrosis, and subsequently cirrhosis of the liver. The absence of anti-fibrotic drugs contributes to the implementation of research to find alternative methods of treatment for this category of patients. In General, the use of autologous multipotent mesenchymal stromal cells is an effective and promising method, and research in this direction should be continued.
Full Text
##article.viewOnOriginalSite##About the authors
I. E. Kotkas
North-Western State Medical University named after I.I. Mechnikov
							Author for correspondence.
							Email: inna.kotkas@yandex.ru
				                					                																			                												                	Russian Federation, 							Saint Petersburg						
V. I. Masurov
North-Western State Medical University named after I.I. Mechnikov
														Email: inna.kotkas@yandex.ru
				                					                																			                												                	Russian Federation, 							Saint Petersburg						
I. G. Bakulin
North-Western State Medical University named after I.I. Mechnikov
														Email: inna.kotkas@yandex.ru
				                					                																			                												                	Russian Federation, 							Saint Petersburg						
N. I. Enukashvili
North-Western State Medical University named after I.I. Mechnikov
														Email: inna.kotkas@yandex.ru
				                					                																			                												                	Russian Federation, 							Saint Petersburg						
Sh. M. Asadulayev
North-Western State Medical University named after I.I. Mechnikov
														Email: inna.kotkas@yandex.ru
				                					                																			                												                	Russian Federation, 							Saint Petersburg						
References
Supplementary files
 
				
			 
					 
						 
						 
				 
  
  
  Email this article
			Email this article 
 Open Access
		                                Open Access Access granted
						Access granted Subscription Access
		                                		                                        Subscription Access
		                                					



